Our news

1655 news items

Research

Efgartigimod reaches phase III in myasthenia gravis

On 06/09/2021

A disorder affecting the neuromuscular junction, Efgartigimod reaches phase III in myasthenia gravis has benefited from relatively intensive therapeutic research for a rare disease, with…